Omega-3 Fatty Acids
Also known as: N-3 fatty acids, EPA, DHA, ALA
This ingredient is classified as unclassified risk (GIRI score: 2.0/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Omega-3 fatty acids from fish or plant sources are broadly recognised as beneficial for cardiovascular health. They are safe at dietary amounts. High supplemental doses (>3 g/day) can impair platelet function. Interaction with blood thinners such as warfarin and aspirin is possible. Choose high-quality, oxidation-tested products.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Omega / EFAs
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Omega-3 Fatty Acids indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 13:59
Evidence Distribution
-
Observational / other LOW evidence YELLOWEffect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis. ↗Bai J et al.. Effect of omega-3 supplementation on metabolic and inflammatory markers in adults with HIV infection: a systematic review and meta-analysis.. Front Nutr. 2026. PMID:41883419.PMID 41883419 ↗Journal Front NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883419/
-
Observational / other LOW evidence YELLOWGlycerophospholipids in dairy cow health and longevity: a review. ↗Sheedy DB et al.. Glycerophospholipids in dairy cow health and longevity: a review.. J Dairy Res. 2026. PMID:41883310.PMID 41883310 ↗Journal J Dairy ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883310/
-
Observational / other LOW evidence YELLOWFish oil-derived eicosapentaenoic and docosahexaenoic acids enhances synthesis of pro-resolving oxylipins and improves growth performance and insulin sensitivity in feedlot cattle. ↗Pittaluga AM et al.. Fish oil-derived eicosapentaenoic and docosahexaenoic acids enhances synthesis of pro-resolving oxylipins and improves growth performance and insulin sensitivity in feedlot cattle.. J Anim Sci. 2026. PMID:41883159.PMID 41883159 ↗Journal J Anim SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883159/
-
Observational / other LOW evidence YELLOWNutritional pathways from treatment to management of sarcopenia in patients with gastric cancer: a narrative review. ↗Swati et al.. Nutritional pathways from treatment to management of sarcopenia in patients with gastric cancer: a narrative review.. Korean J Fam Med. 2026. PMID:41881664.PMID 41881664 ↗Journal Korean J Fam MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41881664/
-
Observational / other LOW evidence YELLOWMetabolomic biomarkers enhance 10-year mortality risk calibration and clinical utility in older heart failure patients: A UK Biobank study. ↗Zeng X et al.. Metabolomic biomarkers enhance 10-year mortality risk calibration and clinical utility in older heart failure patients: A UK Biobank study.. Exp Gerontol. 2026. PMID:41881269.PMID 41881269 ↗Journal Exp GerontolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41881269/
-
Observational / other LOW evidence YELLOWThe Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled… ↗Li L et al.. The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status.. Diabetes Metab Syndr Obes. 2026. PMID:41878258.PMID 41878258 ↗Journal Diabetes Metab Syndr ObesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41878258/
-
Observational / other LOW evidence YELLOWImmunoregulatory role of resolvins in periodontal disease and treatment: a systematic review. ↗Abullais SS et al.. Immunoregulatory role of resolvins in periodontal disease and treatment: a systematic review.. BMC Oral Health. 2026. PMID:41877137.PMID 41877137 ↗Journal BMC Oral HealthYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41877137/
-
Observational / other LOW evidence YELLOWNutraceuticals and the Microbiota-Gut-Brain Axis: A Pathway for Preventing Cognitive Decline. ↗Castillo-Moral u00c1 et al.. Nutraceuticals and the Microbiota-Gut-Brain Axis: A Pathway for Preventing Cognitive Decline.. Nutr Rev. 2026. PMID:41875216.PMID 41875216 ↗Journal Nutr RevYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41875216/
-
Observational / other LOW evidence YELLOWUpcycling walnut (Juglans regia L.) by-products: characterisation of nutritionally relevant bioactive compounds. ↗Campins-Machado FM et al.. Upcycling walnut (Juglans regia L.) by-products: characterisation of nutritionally relevant bioactive compounds.. Food Funct. 2026. PMID:41873665.PMID 41873665 ↗Journal Food FunctYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41873665/
-
Observational / other LOW evidence YELLOWRobustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes. ↗Zuin M et al.. Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes.. J Cardiovasc Med (Hagerstown). 2026. PMID:41870913.PMID 41870913 ↗Journal J Cardiovasc Med (Hagerstown)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41870913/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Omega-3 Fatty Acids. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Omega-3 Fatty Acids
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.